Second medical use patents after Warner-Lambert v Generics

10 DECEMBER 2018

| 1 min read

After the Supreme Court’s ruling in Warner-Lambert v Generics , clinicians and pharmacists can breathe a sigh of relief that they will not be personally exposed to patent litigation.

After the Supreme Court’s ruling in Warner-Lambert v Generics, clinicians and pharmacists can breathe a sigh of relief that they will not be personally exposed to patent litigation. But the decision raises some questions for innovative pharmaceutical companies. How does it impact the incentives available for researching new uses for existing medicines? Our patent experts Alasdair Poore and Mark Pearce discuss the issues.

Our content explained

Every piece of content we create is correct on the date it’s published but please don’t rely on it as legal advice. If you’d like to speak to us about your own legal requirements, please contact one of our expert lawyers.

Second medical use patents after Warner-Lambert v Generics

Our content explained

Further reading

Sending data to the US? What UK organisations need to know about the new UK-US data bridge

Visitors

Existing clients

Staff